Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed uterine leiomyosarcoma
• * Advanced, persistent, or recurrent disease
• * Documented disease progression
• Measurable disease
• * At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
• At least 1 target lesion
• * Tumors within a previously irradiated field are considered nontarget lesions
• Ineligible for higher priority GOG protocols (i.e., any active phase III GOG protocol for the same patient population)
• PATIENT CHARACTERISTICS:
• Age
• Adult
• Performance status
• GOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hepatic
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST ≤ 2.5 times ULN
• Alkaline phosphatase ≤ 2.5 times ULN
• Renal
• Creatinine ≤ 1.5 times ULN
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No neuropathy (sensory or motor) \> grade 1
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• No active infection requiring antibiotics
• No known hypersensitivity to E. coli-derived proteins
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• No prior cytotoxic chemotherapy for the malignancy
• Endocrine therapy
• At least 1 week since prior hormonal therapy for the malignancy
• Concurrent hormone replacement therapy allowed
• Radiotherapy
• See Disease Characteristics
• Recovered from prior radiotherapy
• Surgery
• Recovered from prior surgery
• Other
• Recovered from all other prior therapy
• No prior cancer treatment that would preclude study treatment
• No concurrent amifostine or other protective agents